Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease

被引：0
|
作者：
Muhammed, R. [1 ]
Whyte, L. [1 ]
Protheroe, S. [1 ]
Bremner, R. [1 ]
Haller, W. [1 ]
Wong, T. [1 ]
机构：
[1] Birmingham Childrens Hosp, Gastroenterol, Birmingham, W Midlands, England
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P382
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB TO ORIGINATOR INFLIXIMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
    Muhammed, R.
    Wong, T.
    Haller, W.
    Protheroe, S.
    Whyte, L.
    Bremner, R.
    [J]. GUT, 2016, 65 : A259 - A260
  • [2] COMPARISON OF IMMUNOGENICITY OF BIOSIMILAR INFLIXIMAB AND ORIGINATOR INFLIXIMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE IN REAL LIFE SETTING
    Wahid, A.
    Muhammed, R.
    [J]. GUT, 2017, 66 : A263 - A263
  • [3] Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
    Lichtenstein, Gary R.
    Soonasra, Arif
    Latymer, Mark
    Singh, Sheena
    Feagan, Brian G.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (07) : 691 - 708
  • [4] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [5] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [6] Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar
    Mcclinchie, Madeline G.
    Lakhani, Alyshah
    Abdel-Rasoul, Mahmoud
    Mcnicol, Megan
    Shkhkhalil, Ala K.
    Boyle, Brendan B.
    Maltz, Ross M.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (04): : 499 - 504
  • [7] Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety
    Dipasquale, Valeria
    Romano, Claudio
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (06) : 1228 - 1234
  • [8] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    [J]. Indian Journal of Gastroenterology, 2022, 41 : 446 - 455
  • [9] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Kumar, Peeyush
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Kedia, Saurabh
    Sahu, Pabitra
    Ranjan, Mukesh Kumar
    Mundhra, Sandeep
    Golla, Rithvik
    Kumar, Mukesh
    Virmani, Shubi
    Gupta, Anvita
    Yadav, Nidhi
    Makharia, Govind
    Ahuja, Vineet
    [J]. INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) : 446 - 455
  • [10] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
12345